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Results: Patients with AT were younger and less frequently hypertensive.
Glycoprotein IIb/IIIa inhibitors were more frequently administrated in the
AT group. However, a decrease in the rate of patients with TIMI 3 flow
grade post PCI was observed in the AT group. Peak creatine kinase was
significantly higher in patients with AT while ischemic time was similar for
the 2 groups. Stenting the infarct-related lesion was less frequent than in the
control group. CV mortality at 30 days and at 1-year were higher in the AT
group (11.4 vs. 5.2 %, p=0.016, and 14.6 vs. 7%, p=0.013) respectively. By
multivariate analysis, AT remains an independent predictor of 1-Y mortality
even when adjusted for potential confounders (HR(95%CI):4.95(2.08-
11.77)). These results were unchanged when the propensity score for AT
was introduced into the model.
Conclusions: In the contemporary era of interventional therapy, this large
observational study revealed that routine use of AT in primary PCI with a
baseline TIMI 0 or 1 flow was not associated with an improved outcome.
Prospective studies are warranted to precisely analyse the impact of AT in
such patients and to further investigate its potential benefit.
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Aim: Compare the effectiveness and safety of drug-eluting stent (DES) vs
bare metal stent (BMS) for percutaneous coronary intervention (PCI) in
patients with chronic renal failure (CRF).
Methods: 1126 patients treated by PCI over one year were divided in
4 patients groups, according to the type of stent used (DES vs BMS) and
the creatinin clearance (CrCl). Clinical and angiographic data were pros-
pectively entered into the web-based "Middle-Care" database. Chronic
renal failure (CRF) was defined by a CrCl < 60 ml/min. The occurrence of
cardiovascular (CV) death, MACCE (Death, myocardial infarction and
stroke) and TLR was recorded at one year follow-up. We report the preli-
minary (6 months) results of patients treated between August 2007 and
January 2008.
Results: 497 patients underwent PCI: 250 (50.3%), 120 (24.1%), 81
(16.3%) and 46 (9.3%) patients were allocated in the BMS, DES, BMS
CRF and DES CRF groups respectively. Mean age was 64 +/- 13 years,
82.5% were male, 24.4% had diabetes, 62.1% had an acute coronary syn-
drom (ACS) and 47% multivessel disease. One year follow-up was com-
pleted for 485 (97.6%) patients: 36 (7.1%) patients died, 54 (10.7%) had
MACCE and 35 (6.9%) underwent TLR. The use of DES was associated
with significantly less CV death and MACCE, a trend for less TLR and the
same stent thrombosis (ST) rate compared with BMS use in patients with
and without CRF (figure).
Conclusions: The use of DES appears to be more effective and at least as
safe as BMS at one year follow up in patients with CRF. Final results will be
available for the meeting. 
063
Is it Safe to use Drug Eluting Stents in Older patients? Lessons from
the PAPI registry
Patrick Dupouy (1), Michel Hanssen (2), Emmanuel Teiger (3), Michel
Slama (4), Olivier Wittenberg (5), Janusz Lipiecki (6)
(1) PCVI Hopital Prive d’Antony, Antony, France – (2) Centre Hospitalier
General, Haguenau, France – (3) Hopital Henri Mondor APHP, Creteil,
France – (4) HOpital Antoine Beclere Aphp, Clamart, France – (5) Cen-
tre Hospitalier Prive Beauregard, Marseille, France – (6) Hopital Gabriel
Montpied-Groupe Hospitalier St Jacques-CHU, Clermont-Ferrand,
France
Background: Elderly patients are at higher risk for coronary angioplasty
and few data exist on the safety of drug eluting stent (DES) in this special
population. Objectives: this registry sought to compare bare metal stent (BMS)
and DES short and long term clinical outcome and survival in a cohort of
patients older than 75.
Methods: between September 2007 and august 2008, 2000 patients older
than 75 years old were included in a prospective the multicentric PAPI
registry. Patients were all treated by coronary stenting with either BMS or
DES and were followed for clinical events at the end of the initial hospitalisa-
tion, at 6, 12 and 24 months. Patients were compared according to there DES/
BMS status for the entire cohort and were divided in 3 subgroups according to
there age 75-80, 80-85 and >85 to assess aging influence.
Results: mean age of the total population was 80±3 (75-96). On the overall
population 3318 stents were used for the angioplasty of 3132 lesions. Twenty
seven percent of them were DES. There was a significant decrease of DES use in
older patients (12% patients >85 vs 33% patients <80 p=0.0001). At 6 month
death occured in 3.2% of patients, infarction in 1.5% and stent thrombosis in 1.5%
with no significant difference between type of stent. There was a trend for less
Major Adverse Cardiac events (MACE) in DES patients (6% vs 8%; p=0.07) and
significantly less Major Adverse Cardiac and CerebroVascular events (MACCE)
in DES patients (6% vs 9%; p=0.02). There was less major events for DES than
for BMS patients for the younger group (7%vs13%; p=0.01). In uni or multivariate
analysis stent type was not predictive of adverse event.
Conclusion: PAPI is a multicentric prospective registry aim to evaluate the
outcome of modern coronary angioplasty in patients > 75 years old. DES were
associated with a significant better outcome at 6 month. Thus, at least at 6
month, the use of DES in older patients seems to be safe in older patients.
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